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Laryngeal dystonia or spasmodic dysphonia is characterized 
by involuntary and innapropiate spasms of vocal muscles, 
having the adductor type as the most common one. It is 
chacterized by strain-strangled voice with pitch breaks. 
Diagnosis is made by means of videolaryngostroboscopic 
exam. The treatment of choice is done with botulinum 
toxin directly injected in the muscles responsible for the 
mismatched movement. The aim of this study is to report 
on an adductor- type dysphonia patient and to discuss the 
advantages and observations about this treatment reported 
in the literature.
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INTRODUCTION
Laryngeal dystonia is a speech disorder character-
ized by involuntary contractions of the laryngeal muscles 
involved in the speech producing process. Although in the 
past they were treated as psychosomatic disorders, today 
we know that laryngeal dystonias or spasmodic dyspho-
nias are central-motor processing neurological disorders. 
Koufman1 classifies laryngeal dystonias in four types (ad-
ductor, abductor, mixed and respiratory); the adductor type 
may be further divided in four subtypes depending on 
location (glottic, supraglottic) and the presence of tremor 
(with and without tremor); mixed dystonias are subdivided 
in three, based on the predominant disorder (adductor 
with abductor compensation, abductor with adductor 
compensation) and tremor. The adductor type is more 
frequent and characterized by tense and strangled voice, 
with frequent phonatory breaks and usually tremor due to 
irregularities and inadequate contractions of the muscles 
responsible for vocal cord adduction. In the glottic subtype, 
only those muscles involved in vocal fold adduction suffer 
this irregular contraction, and in the supraglottic, vocal 
folds, ventricular folds and other supraglottic structures 
are involved in the process, and speech fluency is most 
affected in this subtype. Abductor dystonia is less frequent 
and has worse results from Botulin Toxin treatment; it re-
sults from the lack of abductor muscles coordination and 
is clinically characterized by voice fluency breaks, with 
a breathy voice. Respiratory dystonia2 is a rare disease in 
which the irregular spasms do not occur during speech, 
but rather during inhaling, causing inspiratory stridor and 
inadequate respiratory pauses due to vocal folds paradoxi-
cal movements.
Diagnosis of the different dystonias is basically 
carried out by the following exams: general, otorhinolar-
yngological, neurological and stroboscopy. Laryngeal dys-
tonias treatment is based on the injection of Botulin toxin 
directly in the abnormal muscle, identified through direct 
laryngoscopy or by percutaneous punction, monitored by 
flexible naso-laryngeal fibroscopy under local anesthesia 
and/or laryngeal electromyography3. Another injection 
may be necessary and according to some studies it should 
happen in approximately 6 months4,14. Botulin toxin is 
produced by the Clostridiun tetani and it desensitizes the 
neural plaques where acetylcholine is used, thus inhibit-
ing the spasms. It is yet to be defined if Botulin toxin may 
suffer resistance by the laryngeal muscles 6 and if repeated 
injections may cause their definitive desensitization, and 
if type B Botulin toxin may be used in cases resistant to 
type A7,10. The goal of the present study is to report the 
case of a patient with laryngeal dystonia and discuss the 
treatment types mentioned in the literature.
CASE REPORT
N. B., 61 year old Caucasian female, complaining of 
irregular speech breaks without hoarseness or aphonya. 
Symptoms started about 2 years ago, with voice loss after 
intense crying during many hours, and after some days 
her voice gradually returned, however with the aforemen-
tioned alterations. The patient went to a Neurologist and 
was diagnosed with dysarthria. She underwent speech 
therapy for six months, without changes in her vocal 
pattern.
She was assessed by the authors through strobos-
copy, clinical neurological exam and voice lab. The patient 
presented signs of tense voice, vocal tiredness, breathy 
voice, laryngeal pain, loss in voice extension and lack 
of frequency control (oscillation). During examination 
she presented with mild hoarse voice, severe crepitation, 
having an inadequate voice pattern for her physique, 
with short maximum speech time for her gender and age. 
Negative response to auditory masking, thus ruling out the 
possibility of psychogenic dystonia, and she was diagnosed 
as having organic dysphonia due to laryngeal dystonia
Stroboscopy showed mild bilateral vocal tremor, 
more intense in the left vocal cord, no cord structural le-
sions, and no retrocrycoid and interarytenoid edema. She 
had good lamina propria expansion bilaterally without 
glottal gaps.
She was treated with the injection of 5U of type A 
Botulin Toxin (Botox) in the left thyroarytenoid muscle 
through suspension laryngoscopy. Her voice was some-
what breathy in the first week, and after that it became 
stable; she increased her respiratory capacity and maxi-
mum speech time, acquired respiratory pneumophonic 
coordination and better mobility of her phonoarticular 
organs. We then, decided to observe the patient and ana-
lyze her need for another injection of Botulin Toxin.
DISCUSSION
Laryngeal dystonias are involuntary and non-coor-
dinated contractions of the laryngeal muscles involved in 
speech production. They may be classified as adductors, 
abductors or respiratory, depending on the main muscles 
involved. Adductor dystonia is the most common1.
The case reported is about a patient with the ad-
ductor type laryngeal dystonia, and our discussion will 
emphasize this disorder.
The adductor dysphonia causes tense and strangled 
voice, with frequent speech breaks and intense vocal ef-
fort. It may be further divided into glottic and supraglottic 
adductor dysphonia, in the former only those muscles 
responsible for vocal cord adduction contract, while in 
the supraglottic type, the ventricular folds and supraglottic 
structures also play a role. They may be further classified 
according to the presence or not of tremor, and these are 
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different from the essential tremors because they are not 
present during silence and calm breathing1.
Diagnosis is mainly clinical and may be helped by 
stroboscopy and electromyography, revealing irregular 
spasms of the adductor muscles during speech, increased 
and non-coordinated activity of the thyroarytenoid muscles 
in adductor dystonia.
Treatment is carried out through the intramuscular 
injection of Botulin toxin in the affected muscle groups, 
uni or bilateral and guided by endoscopy. Unilateral in-
jection causes approximately the same effect, with less 
side effects8. The dose used is from 0.1U to 10U4. It has 
not been established whether repeated injections may 
cause resistance and if this resistance is caused by specific 
antibodies9. In the patients who develop Botulin toxin A 
resistance, the B type may be used7,10. The therapeutic 
effect lasts for about 6 months, and the injection may be 
repeated after this period, depending on patient comfort 
and symptoms regarding his/her voice. Some studies 
used questionnaires to assess patient life quality changes 
after Botulin toxin injection, and it has proven to be very 
effective regardless of therapeutic time4-5, it remains the 
treatment of choice for patients with laryngeal dystonia.
CONCLUSION
The treatment of choice for spasmodic dystonias 
is the direct intramuscular injection of Botulin toxin and 
after about one week brings the patient’s voice back to 
normal, causing comfort and speech fluency. Unilateral 
injection has the advantage of using a lesser dose, thus 
causing fewer side effects such as breathy voice on the 
days immediately after the injection, and it should be 
preferred in those cases in which stroboscopy and/or elec-
tromyography show greater contraction of a single vocal 
fold. The patient should be analyzed through stroboscopy 
and in the voice lab. Botulin toxin may be injected again 
depending on the results from these exams and patient’s 
comfort and satisfaction.
REFERENCES
 1. Koufman JA, Blalock PD. Classification of laringeal dystonias. [Mo-
nograph online]. North Carolina: Center for Voice Disorders of Wake 
Forest University. URL:http:www.bgsm.edu/voice/classld.html
 2. Lebl MDA, Biase NG, Silveira PLA, Pontes PAL. Distonia laríngea 
respiratória. Rev Bras Oto Out 2003;69(5):721-6.
 3. Teive Hélio AG, Scola Rosana H, Werneck Lineu C et al. O uso da 
toxina botulínica no tratamento da distonia laríngea (disfonia espas-
módica): estudo preliminar com doze pacientes. Arq Neuro-Psiquiatr 
Mar 2001;59(1):97-100.
 4. Blitzer A, Brin MF, Stewart CF. Botulinum toxin management of 
spasmodic dysphonia (laryngeal dystonia): a 12-year experience in 
more than 900 patients. Laryngoscope Oct 1998;108(10):1435-41.
 5. Bhattacharyya N, Tarsy D. Impact on Quality of Life of Botulinum 
Toxin Treatments for Spasmodic Dysphonia and Oromandibular 
Dystonia. Arch Otolaryngol Head Neck Surg 2001;127:389-92.
 6. Smith M, Ford CN. Resistance to Botulinum Toxin Injections for Spas-
modic Dysphonia. Arch Otolaryngol Head Neck Surg 2000;126:533-
5.
 7. Cardoso F. Botulinum toxin type B in the management of dystonia 
non-responsive to botulinum toxin type A. Arq Neuropsiquiatr 2003; 
61(3A):607-10.
 8. Bielamowicz S, Stager SV, Badillo A, Godlewski A. Unilateral versus 
bilateral injections of botulinum toxin in patients with adductor 
spasmodic dysphonia. J Voice Mar 2002;16(1):117-23.
 9. Park JB, Simpson LL, Anderson TD, Sataloff R. Immunologic charac-
terization of spasmodic dysphonia patients who develop resistance 
to botulinum toxin. J Voice Jun 2003;17(2):255-64.
10. Sataloff RT, Heman-Ackah YD, Simpson LL, Park JB, Zwislewski 
A, Sokolow C, Mandel S. Botulinum toxin type B for treatment of 
spasmodic dysphonia: a case report. J Voice Sep 2002;16(3):422-4.
11. Adler C, Bansberg SF, Hentz JG, Ramig LO, Buder EH, Witt K, Edwards 
BW, Krein-Jones k, Caviness JN. Botulinum Toxin Type A for Treating 
Voice Tremor. Arch Neurol Sep 2004;61:1416-20.
12. Sulica L, Blitzer A, Brin MF, Stewart CF. Botulinum toxin management 
of adductor spasmodic dysphonia after failed recurrent laryngeal 
nerve section. Ann Otol Rhinol Laryngol Jun 2003;112(6):499-505.
13. R Leonard, K Kendall. Differentiation of spasmodic and psychoge-
nic dysphonias with phonoscopic evaluation. Laryngoscope Feb 
1999;109(2 Pt 1):295-300.
14. P Klap, MH Marion, A Perrin, E Fresnel-Elbaz. Treatment of spasmodic 
dysphonia with botulinum toxin. Ann Otolaryngol Chir Cervicofac 
Jan 1991;108(8):477-82.
15. Benninger MS, Gardner G, Grywalski C. Outcomes of Botulinum 
Toxin Treatment for Patients With Spasmodic Dysphonia. Arch Oto-
laryngol Head Neck Surg Sep 2001;127:1083-5.
